Medlive Technology Co., Ltd.

SEHK:2192 Stock Report

Market Cap: HK$8.9b

Medlive Technology Future Growth

Future criteria checks 3/6

Medlive Technology is forecast to grow earnings and revenue by 9.8% and 24.4% per annum respectively. EPS is expected to grow by 6.6% per annum. Return on equity is forecast to be 6.9% in 3 years.

Key information

9.8%

Earnings growth rate

6.6%

EPS growth rate

Healthcare Services earnings growth37.5%
Revenue growth rate24.4%
Future return on equity6.9%
Analyst coverage

Low

Last updated14 Apr 2025

Recent future growth updates

Results: Medlive Technology Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 26
Results: Medlive Technology Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Recent updates

What Medlive Technology Co., Ltd.'s (HKG:2192) 25% Share Price Gain Is Not Telling You

May 07
What Medlive Technology Co., Ltd.'s (HKG:2192) 25% Share Price Gain Is Not Telling You

Here's Why Shareholders May Want To Be Cautious With Increasing Medlive Technology Co., Ltd.'s (HKG:2192) CEO Pay Packet

May 01
Here's Why Shareholders May Want To Be Cautious With Increasing Medlive Technology Co., Ltd.'s (HKG:2192) CEO Pay Packet

Medlive Technology (HKG:2192) Shareholders Should Be Cautious Despite Solid Earnings

Apr 21
Medlive Technology (HKG:2192) Shareholders Should Be Cautious Despite Solid Earnings

Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

Apr 09
Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

Optimistic Investors Push Medlive Technology Co., Ltd. (HKG:2192) Shares Up 26% But Growth Is Lacking

Feb 12
Optimistic Investors Push Medlive Technology Co., Ltd. (HKG:2192) Shares Up 26% But Growth Is Lacking

Should You Be Adding Medlive Technology (HKG:2192) To Your Watchlist Today?

Jan 06
Should You Be Adding Medlive Technology (HKG:2192) To Your Watchlist Today?

Be Wary Of Medlive Technology (HKG:2192) And Its Returns On Capital

Dec 04
Be Wary Of Medlive Technology (HKG:2192) And Its Returns On Capital

Investors Shouldn't Be Too Comfortable With Medlive Technology's (HKG:2192) Earnings

Oct 02
Investors Shouldn't Be Too Comfortable With Medlive Technology's (HKG:2192) Earnings

Pinning Down Medlive Technology Co., Ltd.'s (HKG:2192) P/E Is Difficult Right Now

Sep 27
Pinning Down Medlive Technology Co., Ltd.'s (HKG:2192) P/E Is Difficult Right Now

Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

Jul 04
Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

Medlive Technology Co., Ltd.'s (HKG:2192) Business Is Yet to Catch Up With Its Share Price

Apr 08
Medlive Technology Co., Ltd.'s (HKG:2192) Business Is Yet to Catch Up With Its Share Price

Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Feb 20
Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Are Medlive Technology Co., Ltd. (HKG:2192) Investors Paying Above The Intrinsic Value?

Jan 10
Are Medlive Technology Co., Ltd. (HKG:2192) Investors Paying Above The Intrinsic Value?

Medlive Technology Co., Ltd.'s (HKG:2192) Intrinsic Value Is Potentially 20% Below Its Share Price

Sep 27
Medlive Technology Co., Ltd.'s (HKG:2192) Intrinsic Value Is Potentially 20% Below Its Share Price

Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Jul 10
Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Medlive Technology Co., Ltd. (HKG:2192) Shares Slammed 28% But Getting In Cheap Might Be Difficult Regardless

May 11
Medlive Technology Co., Ltd. (HKG:2192) Shares Slammed 28% But Getting In Cheap Might Be Difficult Regardless

Robust Earnings May Not Tell The Whole Story For Medlive Technology (HKG:2192)

May 02
Robust Earnings May Not Tell The Whole Story For Medlive Technology (HKG:2192)

Results: Medlive Technology Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 26
Results: Medlive Technology Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Here's What's Concerning About Medlive Technology's (HKG:2192) Returns On Capital

Feb 06
Here's What's Concerning About Medlive Technology's (HKG:2192) Returns On Capital

There Are Reasons To Feel Uneasy About Medlive Technology's (HKG:2192) Returns On Capital

Oct 31
There Are Reasons To Feel Uneasy About Medlive Technology's (HKG:2192) Returns On Capital

Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

Jul 14
Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

These Analysts Just Made A Massive Downgrade To Their Medlive Technology Co., Ltd. (HKG:2192) EPS Forecasts

Apr 03
These Analysts Just Made A Massive Downgrade To Their Medlive Technology Co., Ltd. (HKG:2192) EPS Forecasts

Is Medlive Technology Co., Ltd. (HKG:2192) Worth HK$9.5 Based On Its Intrinsic Value?

Feb 22
Is Medlive Technology Co., Ltd. (HKG:2192) Worth HK$9.5 Based On Its Intrinsic Value?

Earnings and Revenue Growth Forecasts

SEHK:2192 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20271,1834182242743
12/31/20269443801742524
12/31/20257263231441774
12/31/202455831587108N/A
9/30/202452030372100N/A
6/30/20244822905792N/A
3/31/20244472666397N/A
12/31/202341224269102N/A
9/30/20233842166990N/A
6/30/20233561896979N/A
3/31/20233351536978N/A
12/31/20223141177077N/A
9/30/2022300835157N/A
6/30/2022286483236N/A
3/31/2022285443740N/A
12/31/2021284414244N/A
9/30/2021270557173N/A
6/30/202125570100101N/A
3/31/202123478105106N/A
12/31/202021485110111N/A
12/31/2019122312628N/A
12/31/201883141922N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2192's forecast earnings growth (9.8% per year) is above the savings rate (2.4%).

Earnings vs Market: 2192's earnings (9.8% per year) are forecast to grow slower than the Hong Kong market (10.6% per year).

High Growth Earnings: 2192's earnings are forecast to grow, but not significantly.

Revenue vs Market: 2192's revenue (24.4% per year) is forecast to grow faster than the Hong Kong market (8.5% per year).

High Growth Revenue: 2192's revenue (24.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 2192's Return on Equity is forecast to be low in 3 years time (6.9%).


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/07 05:23
End of Day Share Price 2025/05/07 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medlive Technology Co., Ltd. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shuo SongCitic Securities Co., Ltd.
Luoxin JiangCitic Securities Co., Ltd.
Zhu ChenCitic Securities Co., Ltd.